Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRIB-PHOS: Sevelamer in Early CKD
NCT00806481Phase 2Completed
- Sponsor
- University Hospitals Birmingham
- Start
- Feb 2009
- Primary completion
- Oct 2011
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing Sevelamer Carbonate with Placebo (2 arms). Primary endpoint: Change in left ventricular mass at 36 weeks. Started Feb 2009; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT00806481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00806481.